The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Open accessAbstract
OBJECTIVE: Although counseling is a required part of office-based buprenorphine treatment of opioid use disorders, the nature of what constitutes appropriate counseling is unclear and controversial. The authors review the literature on the role, nature, and intensity of behavioral interventions in office-based buprenorphine treatment. METHOD: The authors conducted a review of randomized controlled studies testing the efficacy of adding a behavioral intervention to buprenorphine maintenance treatment. RESULTS: Four key studies showed no benefit from adding a behavioral intervention to buprenorphine plus medical management, and four studies indicated some benefit for specific behavioral interventions, primarily contingency management. The authors examined the findings from the negative trials in the context of six questions: 1) Is buprenorphine that effective? 2) Is medical management that effective? 3) Are behavioral interventions that ineffective in this population? 4) How has research design affected the results of studies of buprenorphine plus behavioral treatment? 5) What do we know about subgroups of patients who do and those who do not seem to benefit from behavioral interventions? 6) What should clinicians aim for in terms of treatment outcome in buprenorphine maintenance? CONCLUSIONS: High-quality medical management may suffice for some patients, but there are few data regarding the types of individuals for whom medical management is sufficient. Physicians should consider a stepped-care model in which patients may begin with relatively nonintensive treatment, with increased intensity for patients who struggle early in treatment. Finally, with 6-month retention rates seldom exceeding 50% and poor outcomes following dropout, we must explore innovative strategies for enhancing retention in buprenorphine treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, studies of traditional evidence-based behavioral interventions with buprenorphine/naloxone treatment have failed to demonstrate significant reductions in opioid use compared to treatment as usual (TAU) 7.”
From Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study (2023) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03140.x · Cited by 856
A 33-Year Follow-up of Narcotics Addicts
Hser, Y., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.503 · Cited by 849
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA · doi:10.1001/jama.1993.03500150065028 · Cited by 827
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T. E., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 610
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Self-citationHser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Higgins, S. T., Wong, C. J., Badger, G. J., Ogden, D., & Dantona, R. L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.1.64 · Cited by 352
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Flagged first, then by citations
Research works printed but not linked: 3
- [23]Ball JC Ross A The Effectiveness of Methadone Maintenance Treatment 1991 New York Springer-Verlag
- [44]Institute of Medicine Panel on Handling Data in Clinical Trials. The Prevention and Treatment of Missing Data in Clinical Trials 2010 Washington, DC The National Academies Press 24983040
- [64]Hoffman KA McCarty D Miller PM Improving the quality of addiction treatment Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders 2013 San Diego, CA Academic Press 579 588
Cited by
Sorted by citations
Items 201–210 of 210
Ma, L., Steinberg, J. L., Bjork, J. M., Woisard, K., Zuniga, E. A., Cunningham, K. A., & Moeller, F. G. (2025) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2025.112034
Thakrar, A. P., & Rastegar, D. A. (2025) · doi:10.1093/med/9780197796207.003.0006
Chapter 1. Treatment of Substance Use Disorders
Kast, K. A., McHugh, R. K., & Marcovitz, D. E. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg01
Kleinman, M. B., Anvari, M. S., Bradley, V. D., Felton, J. W., Belcher, A. M., Seitz‐Brown, C. J., Greenblatt, A. D., Dean, D., Bennett, M., & Magidson, J. F. (2023) · Figshare · doi:10.6084/m9.figshare.22620715
Kleinman, M. B., Anvari, M. S., Bradley, V. D., Felton, J. W., Belcher, A. M., Seitz‐Brown, C. J., Greenblatt, A. D., Dean, D., Bennett, M., & Magidson, J. F. (2023) · Figshare · doi:10.6084/m9.figshare.22620712
Amura, C. R., Sorrell, T. R., Weber, M., Alvarez, A., Beste, N., Hollins, U., & Cook, P. F. (2022) · Figshare · doi:10.6084/m9.figshare.17798525
Persistence and relapse of problematic substance use
Toegel, F., Eckard, M. L., Nall, R. W., & Craig, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22365-5.00011-1
Kelly, D., Lites, A., Campbell, A., & Bottyan, T. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001731
Henderson, C. R., Walker, S., Lloyd, Z., Gibbs, D., Romero, L., & Stoove, P. M. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105468
Metadata
- Authors
- Carroll, K. M., & Weiss, R. D.
- Affiliations
- Harvard University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2017-08
- Volume
- 174
- Issue
- 8
- Pages
- 738-747
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5474206
- OpenAlex
- W2566316894
- Cited by
- 211
- References
- 67
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 21 · 2023: 21 · 2022: 33 · 2021: 35 · 2020: 29 · 2019: 29 · 2018: 20 · 2017: 5
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Institute on Drug Abuse (K24DA022288, P50DA009241, UG1DA015831)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine maintenance treatment, opioid use disorder, behavioral interventions, contingency management, office-based opioid treatment, medical management, stepped care, treatment retention, counseling, treatment discontinuation
- MeSH terms
- Behavior Therapy, Buprenorphine, Combined Modality Therapy, Heroin Dependence, Humans, Long-Term Care, Methadone, Opioid-Related Disorders, Outcome and Process Assessment, Health Care, Patient Compliance, Randomized Controlled Trials as Topic, Cocaine-Related Disorders, Patient Preference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
